Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.61 |
| ▸ | TK2 | O00142 | 2/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582684 | 0.88 | PYGM (0.66) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6758892 | 0.88 | PYGM (0.66) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL8369203 | 0.87 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6829043 | 0.86 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL27708288 | 0.86 | PYGM (0.60) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6530419 | 0.84 | PYGM (0.61) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6882436 | 0.84 | PYGM (0.61) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10644984 | 0.83 | PYGM (0.66) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10644978 | 0.83 | PYGM (0.66) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10645083 | 0.83 | PYGM (0.66) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11000547-B2 | Compositions related to rna in circularized form | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-11 | — | — | US | claimed |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-04 | — | — | US | claimed |
| US-20180169146-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | claimed |
| EP-3303377-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | Dana-Farber Cancer Institute, Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | claimed |
| WO-2016197121-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-08 | — | — | WO | claimed |
| US-9334495-B2 | Minor groove binder (MGB)-oligonucleotide miRNA antagonists | ELITECHGROUP B.V. (NL) | 2016-05-10 | — | — | US | claimed |
| EP-2547769-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | Elitech Holding B.V. (NL) | 2013-01-23 | — | — | EP | claimed |
| US-20110172289-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. | 2011-07-14 | — | — | US | claimed |
| WO-2011066312-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. (NL) | 2011-06-03 | — | — | WO | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-20260137713-A1 | POLYNUCLEOTIDES FOR SILENCING TRANSCRIPT VARIANT 1 OF ASSEMBLY FACTOR FOR SPINDLE MICROTUBULES AND APPLICATIONS THEREOF | TAIPEI MEDICAL UNIVERSITY (TW) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12617822-B2 | Arc-based capsids and uses thereof | Aera Therapeutics, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4731258-A1 | LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF | Providence Therapeutics Holdings Inc. (CA) | 2026-04-29 | — | — | EP | disclosed |
| US-20040198640-A1 | Stabilized polynucleotides for use in RNA interference | DHARMACON, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004045543-A2 | FUNCTIONAL AND HYPERFUNCTIONAL SIRNA | DHARMACON, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-0506892-A4 | BORONATED NUCLEOSIDES | — | 1993-03-31 | — | — | EP | disclosed |
| EP-0506892-A1 | BORONATED NUCLEOSIDES. | BORON BIOLOG INC (US) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009048-A1 | BORONATED NUCLEOSIDES | BARON BIOLOGICALS, INC. (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198640-A1 | Stabilized polynucleotides for use in RNA interference | NSUN2, NSUN3, TRDMT1 | PYGM 1110/4885TK2 142/4885SLC28A1 1114/4885 |
| US-20260137713-A1 | POLYNUCLEOTIDES FOR SILENCING TRANSCRIPT VARIANT 1 OF ASSEMBLY FACTOR FOR SPINDLE MICROTUBULES AND APPLICATIONS THEREOF | UPF1, NOTCH1, DVL1 | PYGM 2240/4885TK2 2746/4885SLC28A1 2354/4885 |
| US-20180169146-A1 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY | NSUN2, NSUN3, TRDMT1 | PYGM 3962/4885TK2 32/4885SLC28A1 1515/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | PYGM 15/4885TK2 313/4885SLC28A1 167/4885 |
| US-20110172289-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ZFR, SLIRP, CNBP | PYGM 3837/4885TK2 3738/4885SLC28A1 2580/4885 |
| US-11000547-B2 | Compositions related to rna in circularized form | NSUN3, METTL16, FBL | PYGM 1530/4885TK2 2718/4885SLC28A1 4018/4885 |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | PNP, RNGTT, NSUN2 | PYGM 846/4885TK2 151/4885SLC28A1 41/4885 |
| US-12617822-B2 | Arc-based capsids and uses thereof | RBM28, PHAX, SRP9 | PYGM 2462/4885TK2 4325/4885SLC28A1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.